Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Pacific Biosciences of California Is Surging Today

By Cory Renauer - Aug 3, 2017 at 4:02PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The sequencing company topped off a solid second-quarter earnings report with news of a big order from its best customer.

What happened

Shares of Pacific Biosciences of California (PACB -0.37%), a purveyor of high-accuracy genomic sequencing kits, is marching higher after reporting second-quarter earnings and a big order from a leading genetic-services provider. The news lifted the stock about 13.7% higher as of 3:42 p.m. EDT on Thursday.

So what 

Stripping away significant contractual revenue recorded last year, second-quarter product and service sales rose 17% higher than the same period last year, to $20.1 million. Perhaps more importantly, total operating expenses rose just 13% on the year, which suggests the company is becoming increasingly efficient.

Stock market trader pointing up toward a multi-panel display.

Image source: Getty Images.

For dessert yesterday, Pacific Biosciences treated investors to a 10-unit Sequel System purchase announcement. The company had installed 110 of the systems as of this January when it announced a major upgrade that expanded its potential applications. Novogene already has 10 of the systems installed, and its intention to double its capacity suggests the upgrade is driving demand for Sequel Systems and the proprietary consumable products necessary to run them.

Now what

A secondary share offering helped Pacific Biosciences raise about $65 million during the second quarter, which boosted its cash balance to about $102 million at the end of June. With sales on a steep upward trajectory, management stated it has no plans to visit the equity tap again.

The company lost $49.4 million in the first half of the year. If the growth we've seen so far this year continues, it looks like another share offering might not be necessary -- but it will be tight.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pacific Biosciences of California, Inc. Stock Quote
Pacific Biosciences of California, Inc.
$5.37 (-0.37%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.